Search

Author/Creator Siddiqi, T.

2. AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1. (June 2017)

Authors:
Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Wiezorek, J.; Go, W.Y.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (June 2017)

Authors:
Nastoupil, L.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S.; Sportelli, P.; Miskin, H.P.; Purdom, M.A.; Weiss, M.S.; Fowler, N.H.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
112
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (June 2017)

Authors:
Lunning, M.A.; Vose, J.M.; Bierman, P.J.; Bociek, G.; Schreeder, M.T.; Siddiqi, T.; Blumel, S.M.; Cutter, K.; Pauli, E.K.; Bui, D.; Sportelli, P.; Miskin, H.P.; Purdom, M.; Weiss, M.S.; Fowler, N.H.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
266
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B‐NHL TREATED WITH THE CD19‐DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001). (June 2017)

Authors:
Abramson, J.; Palomba, M.L.; Gordon, L.; Lunning, M.; Arnason, J.; Wang, M.; Forero‐Torres, A.; Albertson, T.; Allen, T.; Sutherland, C.; Xie, B.; Garcia, J.; Siddiqi, T.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
138
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022)

Authors:
Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1048
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER-RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA. (23rd June 2022)

Authors:
Davids, M.; Sharman, J.; Ghia, P.; Woyach, J.; Jurczak, W.; Siddiqi, T.; Miranda, P.; Shahkarami, M.; Yu, T.; Emeribe, U.; Byrd, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT. (23rd June 2022)

Authors:
Moreno, C.; Wierda, W. G.; Barr, P. M.; Siddiqi, T.; Allan, J. N.; Kipps, T. J.; Trentin, L.; Jacobs, R.; Jackson, S.; Tedeschi, A.; Opat, S.; Bannerji, R.; Kuss, B. J.; Croner, L. J.; Szafer-Glusman, E.; Zhou, C.; Szoke, A.; Dean, J. P.; Ghia, P.; Tam, C. S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
567
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (23rd June 2022)

Authors:
Barrientos, J. C.; Barr, P. M.; Mato, A. R.; Tam, C. S.; Ghia, P.; Moreno, C.; Kay, N. E.; Siddiqi, T.; Szafer-Glusman, E.; Zhou, C.; Neumayr, L.; Krigsfeld, G.; Wierda, W. G.; Shanafelt, T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1758
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗